Mereo BioPharma

37 articles with Mereo BioPharma

• Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)

  6/2/2021

  Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced positive data from an interim analysis of an investigator-initiated study of alvelestat in patients with Bronchiolitis Obliterans Syndrome following hematopoietic stem cell transplantation.

• Mereo BioPharma to Participate in a Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference

  5/27/2021

  Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Thursday, June 3, 2021 at 8:00am Eastern Time.

• Mereo BioPharma to Hold Virtual R&D Day on Thursday, May 13, 2021

  5/4/2021

  Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced it will host a virtual R&D day on Thursday, May 13, 2021 to review the Company’s etigilimab program, highlighting studies in ovarian cancer including Clear-cell ovarian cancer, Cervical cancer and Sarcoma.

• Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference

  2/18/2021

  Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 8:00am Eastern Time.

• Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

  2/12/2021

  Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the closing of its previously announced underwritten public offering of 39,675,000 American Depositary Shares (“ADSs”), at a public offering price of $2.90 per ADS, which includes 5,175,000 additional ADSs issued upon the exercise in full of the underwriters’ option to

• Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares

  2/9/2021

  Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering.

• Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development

  11/23/2020

  Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announces the appointment of Suba Krishnan, M.D. as Senior Vice President of Clinical Development, effective December 7, 2020.

• Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020

  11/16/2020

  Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced it will host a virtual R&D day on Tuesday, November 24, to review the Company’s key pipeline programs including etigilimab for solid tumors and alvelestat for alpha-1 antitrypsin deficiency and COVID-19 respiratory disease.

• Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference

  11/10/2020

  Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20am Eastern Time. A live audio webcast of the presentation can be accessed through the Inve

• 

  BioSpace Movers & Shakers, Oct. 23

  10/23/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
• 

  BioSpace Global Roundup, Oct. 22

  10/22/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs

  10/20/2020

  Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced the appointment of Christine Fox, CPA, as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs.

• Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)

  10/19/2020

  On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020

• Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update

  9/29/2020

  Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announces unaudited interim financial results for the six months ended June 30, 2020 and provides a corporate update.

• Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta

  9/24/2020

  Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announces that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to setrusumab for the treatment of osteogenesis imperfecta.

• Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease

  8/25/2020

  Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the initiation of a Phase 1b/2 placebo-controlled clinical trial to evaluate the safety and efficacy of alvelestat in hospitalized, adult patients with moderate to severe COVID-19 respiratory disease.

• Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development

  6/30/2020

  Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the appointments of John Lewicki, PhD, as Chief Scientific Officer, and Ann Kapoun, PhD, as Senior Vice President of Translational Research and Development.

• Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019

  6/16/2020

  Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced financial results for the 12 months ended December 31, 2019.

• Mereo BioPharma Announces Completion of $70 Million Private PlacementPlans to Develop Etigilimab (Anti-TIGIT) Alongside Rare Disease Product Portfolio

  6/4/2020

  Mereo BioPharma Group plc announces the completion of a $70 million private placement with a number of new and existing U.S based institutional and accredited investors.

• Business Update and Directorate Change

  3/27/2020

  Mereo BioPharma Group plc today provided a general business update, including a current assessment of the impact of  the coronavirus disease (COVID-19)  pandemic on the business. The Company also announced a directorate change. Business Update The Company has provided an update on the setrusumab and alve